JP2019531072A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531072A5 JP2019531072A5 JP2019514776A JP2019514776A JP2019531072A5 JP 2019531072 A5 JP2019531072 A5 JP 2019531072A5 JP 2019514776 A JP2019514776 A JP 2019514776A JP 2019514776 A JP2019514776 A JP 2019514776A JP 2019531072 A5 JP2019531072 A5 JP 2019531072A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- adapter
- target
- primer
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 346
- 108020004707 nucleic acids Proteins 0.000 claims description 328
- 102000039446 nucleic acids Human genes 0.000 claims description 328
- 125000003729 nucleotide group Chemical group 0.000 claims description 263
- 239000002773 nucleotide Substances 0.000 claims description 259
- 238000000034 method Methods 0.000 claims description 192
- 230000003321 amplification Effects 0.000 claims description 90
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 90
- 230000000295 complement effect Effects 0.000 claims description 59
- 238000003752 polymerase chain reaction Methods 0.000 claims description 55
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 49
- 238000002360 preparation method Methods 0.000 claims description 33
- 239000002299 complementary DNA Substances 0.000 claims description 32
- 238000003786 synthesis reaction Methods 0.000 claims description 31
- 239000011324 bead Substances 0.000 claims description 30
- 229960002685 biotin Drugs 0.000 claims description 27
- 239000011616 biotin Substances 0.000 claims description 27
- 235000020958 biotin Nutrition 0.000 claims description 25
- 238000005406 washing Methods 0.000 claims description 24
- 238000004458 analytical method Methods 0.000 claims description 23
- 230000005298 paramagnetic effect Effects 0.000 claims description 23
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 229930024421 Adenine Natural products 0.000 claims description 18
- 229960000643 adenine Drugs 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 17
- 108010090804 Streptavidin Proteins 0.000 claims description 15
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 102000003960 Ligases Human genes 0.000 claims description 9
- 108090000364 Ligases Proteins 0.000 claims description 9
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 230000002441 reversible effect Effects 0.000 claims description 6
- 229940113082 thymine Drugs 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 229940104302 cytosine Drugs 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 229940035893 uracil Drugs 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 230000000865 phosphorylative effect Effects 0.000 claims description 3
- 239000013615 primer Substances 0.000 description 277
- 239000000523 sample Substances 0.000 description 95
- 239000000047 product Substances 0.000 description 82
- 238000012163 sequencing technique Methods 0.000 description 67
- 108090000623 proteins and genes Proteins 0.000 description 46
- 238000000137 annealing Methods 0.000 description 40
- 108091028043 Nucleic acid sequence Proteins 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 35
- 206010028980 Neoplasm Diseases 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 33
- 230000008707 rearrangement Effects 0.000 description 33
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 32
- 239000012634 fragment Substances 0.000 description 30
- 239000002585 base Substances 0.000 description 25
- 239000000758 substrate Substances 0.000 description 21
- 108091034117 Oligonucleotide Proteins 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 125000005647 linker group Chemical group 0.000 description 17
- 238000009396 hybridization Methods 0.000 description 16
- 230000000903 blocking effect Effects 0.000 description 15
- 102100034343 Integrase Human genes 0.000 description 14
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 14
- 230000005291 magnetic effect Effects 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 238000012408 PCR amplification Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 230000000670 limiting effect Effects 0.000 description 13
- 238000007481 next generation sequencing Methods 0.000 description 13
- 230000000711 cancerogenic effect Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 10
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 10
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 10
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 10
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 10
- 238000010804 cDNA synthesis Methods 0.000 description 10
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 10
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 10
- 201000005202 lung cancer Diseases 0.000 description 10
- 208000020816 lung neoplasm Diseases 0.000 description 10
- 230000008439 repair process Effects 0.000 description 10
- 231100000315 carcinogenic Toxicity 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 101100393821 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GSP2 gene Proteins 0.000 description 7
- 108010006785 Taq Polymerase Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000003100 immobilizing effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000010008 shearing Methods 0.000 description 6
- 102100022887 GTP-binding nuclear protein Ran Human genes 0.000 description 5
- 101000774835 Heteractis crispa PI-stichotoxin-Hcr2o Proteins 0.000 description 5
- 101000620756 Homo sapiens GTP-binding nuclear protein Ran Proteins 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 5
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000000527 sonication Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 231100000357 carcinogen Toxicity 0.000 description 4
- 239000003183 carcinogenic agent Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 235000011178 triphosphate Nutrition 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000005549 deoxyribonucleoside Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- -1 nucleoside triphosphates Chemical class 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 2
- HRFIATJPGFXBNN-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;2-[2-(2-hydroxyethoxy)ethoxy]ethanol Chemical compound OCCOCCOCCO.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 HRFIATJPGFXBNN-UFLZEWODSA-N 0.000 description 2
- BUVSBIKCBLHNCG-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;azide Chemical compound [N-]=[N+]=[N-].N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 BUVSBIKCBLHNCG-UFLZEWODSA-N 0.000 description 2
- 101150023956 ALK gene Proteins 0.000 description 2
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 2
- 108090001008 Avidin Chemical group 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 108010010677 Phosphodiesterase I Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229950004272 brigatinib Drugs 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004252 chorionic villi Anatomy 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 208000010932 epithelial neoplasm Diseases 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 229960004836 regorafenib Drugs 0.000 description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- JGSMCYNBVCGIHC-QPEQYQDCSA-N (3z)-3-[(4-hydroxyphenyl)methylidene]-5,6-dimethoxy-1h-indol-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)\C1=C/C1=CC=C(O)C=C1 JGSMCYNBVCGIHC-QPEQYQDCSA-N 0.000 description 1
- ODPGGGTTYSGTGO-UHFFFAOYSA-N 1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea Chemical compound C1CN(CC)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)NC(C=C1)=CC=C1OC1=CC(NC)=NC=N1 ODPGGGTTYSGTGO-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QQWUGDVOUVUTOY-UHFFFAOYSA-N 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)C(C)C QQWUGDVOUVUTOY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- MGGBYMDAPCCKCT-UHFFFAOYSA-N ASP-3026 Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=NC=1NC1=CC=CC=C1S(=O)(=O)C(C)C MGGBYMDAPCCKCT-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 0 CC(C1)OC(C*)C1OP(O)(O*)S Chemical compound CC(C1)OC(C*)C1OP(O)(O*)S 0.000 description 1
- GHBLYTHEZWTDBL-RAMGSTBQSA-N CN(C)CN(CCCC[C@@H]([C@H]1N2)SCC1NC2=O)C=O Chemical compound CN(C)CN(CCCC[C@@H]([C@H]1N2)SCC1NC2=O)C=O GHBLYTHEZWTDBL-RAMGSTBQSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100417166 Caenorhabditis elegans rpi-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Chemical group C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100029075 Exonuclease 1 Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 101150077555 Ret gene Proteins 0.000 description 1
- 101150035397 Ros1 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006154 adenylylation Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 108010027090 biotin-streptavidin complex Proteins 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- HFCFMRYTXDINDK-WNQIDUERSA-N cabozantinib malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 HFCFMRYTXDINDK-WNQIDUERSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 108091092259 cell-free RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- 210000002726 cyst fluid Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Chemical group CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical group C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229950003968 motesanib Drugs 0.000 description 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical group NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- OAKGNIRUXAZDQF-TXHRRWQRSA-N retaspimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OAKGNIRUXAZDQF-TXHRRWQRSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000001963 scanning near-field photolithography Methods 0.000 description 1
- 229950003647 semaxanib Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 208000030829 thyroid gland adenocarcinoma Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000025444 tumor of salivary gland Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 238000012049 whole transcriptome sequencing Methods 0.000 description 1
- YCGBUPXEBUFYFV-UHFFFAOYSA-N withaferin A Natural products CC(C1CC(=C(CO)C(=O)O1)C)C2CCC3C4CC5OC56C(O)C=CC(O)C6(C)C4CCC23C YCGBUPXEBUFYFV-UHFFFAOYSA-N 0.000 description 1
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395339P | 2016-09-15 | 2016-09-15 | |
| US62/395,339 | 2016-09-15 | ||
| PCT/US2017/051924 WO2018053362A1 (en) | 2016-09-15 | 2017-09-15 | Methods of nucleic acid sample preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531072A JP2019531072A (ja) | 2019-10-31 |
| JP2019531072A5 true JP2019531072A5 (https=) | 2021-11-11 |
| JP6997772B2 JP6997772B2 (ja) | 2022-01-18 |
Family
ID=61619260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514776A Active JP6997772B2 (ja) | 2016-09-15 | 2017-09-15 | 核酸サンプル調製の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10704082B2 (https=) |
| EP (2) | EP3933039A1 (https=) |
| JP (1) | JP6997772B2 (https=) |
| CN (1) | CN109937254B (https=) |
| AU (1) | AU2017328950B2 (https=) |
| CA (1) | CA3037185A1 (https=) |
| ES (1) | ES2903357T3 (https=) |
| WO (1) | WO2018053362A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2847353B1 (en) | 2012-05-10 | 2022-01-19 | The General Hospital Corporation | Methods for determining a nucleotide sequence |
| EP3099820A4 (en) | 2014-01-27 | 2018-01-03 | The General Hospital Corporation | Methods of preparing nucleic acids for sequencing |
| WO2018053365A1 (en) | 2016-09-15 | 2018-03-22 | ArcherDX, Inc. | Methods of nucleic acid sample preparation for analysis of cell-free dna |
| US20220282305A1 (en) * | 2016-09-15 | 2022-09-08 | Archerdx, Llc | Methods of nucleic acid sample preparation |
| US10704082B2 (en) | 2016-09-15 | 2020-07-07 | ArcherDX, Inc. | Methods of nucleic acid sample preparation |
| ES2940620T3 (es) * | 2016-11-02 | 2023-05-09 | Archerdx Llc | Métodos de preparación de muestras de ácido nucleico para la secuenciación del repertorio inmunitario |
| CN114144188B (zh) * | 2019-05-21 | 2024-05-28 | 台湾地区"中央研究院" | 放大及检测核糖核酸(rna)片段的方法 |
| EP4012029B1 (en) * | 2019-08-09 | 2024-05-29 | GeneMind Biosciences Company Limited | Method for capturing nucleic acid molecule, preparation method for nucleic acid library, and a sequencing method |
| EP4055188A4 (en) * | 2019-11-05 | 2023-11-22 | Ultima Genomics, Inc. | METHOD FOR PRODUCING A LIBRARY OF POLYNUCLEOTIDE MOLECULES |
| CN115038795B (zh) * | 2019-12-04 | 2026-03-20 | 贝克顿·迪金森公司 | 捕获磁珠介导的单颗粒中核酸靶标的分子条形码编码及用于其的组合物 |
| MX2023001400A (es) * | 2020-09-11 | 2023-04-25 | Illumina Cambridge Ltd | Metodos para enriquecer una secuencia diana a partir de una genoteca de secuenciación usando adaptadores de horquilla. |
| WO2022146773A1 (en) * | 2020-12-29 | 2022-07-07 | Nuprobe Usa, Inc. | Methods and compositions for sequencing and fusion detection using ligation tail adapters (lta) |
| EP4341436A1 (en) | 2021-05-19 | 2024-03-27 | Seqstant GmbH | Method for parallel real-time sequence analysis |
| CN118028444A (zh) * | 2022-09-16 | 2024-05-14 | 中国疾病预防控制中心传染病预防控制所 | 一种基因测序方法、装置、设备和介质 |
| CN119278276A (zh) * | 2022-09-16 | 2025-01-07 | 中国疾病预防控制中心传染病预防控制所 | 一种基因测序方法、装置、设备和介质 |
| USD1069156S1 (en) | 2023-04-10 | 2025-04-01 | Becton, Dickinson And Company | Dispensing device |
| WO2026024817A1 (en) * | 2024-07-24 | 2026-01-29 | Guardant Health, Inc. | Methods and compositions for anchored multiplex ngs workflows |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5157032A (en) | 1985-01-18 | 1992-10-20 | The Trustees Of Columbia University In The City Of New York | Mixed ligand complexes and uses thereof as binding agents and probes to DNA |
| US4868104A (en) | 1985-09-06 | 1989-09-19 | Syntex (U.S.A.) Inc. | Homogeneous assay for specific polynucleotides |
| US6027913A (en) | 1988-01-28 | 2000-02-22 | Sommer; Steven S. | Nucleic acid amplification with direct sequencing |
| US5374524A (en) | 1988-05-10 | 1994-12-20 | E. I. Du Pont De Nemours And Company | Solution sandwich hybridization, capture and detection of amplified nucleic acids |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| WO1991001384A1 (en) | 1989-07-11 | 1991-02-07 | Gen-Probe, Incorporated | Nucleic acid sequence amplification methods utilizing a transcription complex |
| US6087101A (en) | 1990-05-18 | 2000-07-11 | Gruelich; Karl Otto | Optical characterization of nucleic acids and oligonucleotides |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| US5604098A (en) | 1993-03-24 | 1997-02-18 | Molecular Biology Resources, Inc. | Methods and materials for restriction endonuclease applications |
| US6063566A (en) | 1994-05-13 | 2000-05-16 | The Scripps Research Institute | Catalytic RNA molecules |
| US5846719A (en) | 1994-10-13 | 1998-12-08 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
| US5565340A (en) | 1995-01-27 | 1996-10-15 | Clontech Laboratories, Inc. | Method for suppressing DNA fragment amplification during PCR |
| US5556771A (en) | 1995-02-10 | 1996-09-17 | Gen-Probe Incorporated | Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification |
| US6013439A (en) | 1995-12-22 | 2000-01-11 | Dade Behring Marburg Gmbh | Detection of differences in nucleic acids |
| CA2239683A1 (en) | 1995-12-22 | 1997-07-03 | Dade Behring Marburg Gmbh | Homogeneous amplification and detection of nucleic acids |
| US5827658A (en) | 1996-08-09 | 1998-10-27 | The United States Of America As Reprsented By The Department Of Health And Human Services | Isolation of amplified genes via cDNA subtractive hybridization |
| US5861251A (en) | 1996-10-15 | 1999-01-19 | Bioneer Corporation | Lyophilized reagent for polymerase chain reaction |
| US6225062B1 (en) | 1996-11-12 | 2001-05-01 | Visible Genetics Inc. | Method and kit for direct isothermal sequencing of nucleic acids |
| US6482590B1 (en) | 1996-12-20 | 2002-11-19 | Aventis Behring Gmbh | Method for polynucleotide amplification |
| US20020061532A1 (en) | 1997-02-14 | 2002-05-23 | Mosaic Technologies, Inc. | Method and apparatus for performing amplification of nucleic acids on supports |
| US6365346B1 (en) | 1998-02-18 | 2002-04-02 | Dade Behring Inc. | Quantitative determination of nucleic acid amplification products |
| US6235502B1 (en) | 1998-09-18 | 2001-05-22 | Molecular Staging Inc. | Methods for selectively isolating DNA using rolling circle amplification |
| US6197554B1 (en) | 1998-11-20 | 2001-03-06 | Shi-Lung Lin | Method for generating full-length cDNA library from single cells |
| US6200757B1 (en) | 1999-01-19 | 2001-03-13 | Dade Behring Inc. | Method for controlling the extension of an oligonucleotide |
| US7074556B2 (en) | 1999-03-02 | 2006-07-11 | Invitrogen Corporation | cDNA synthesis improvements |
| WO2000070095A2 (en) | 1999-05-17 | 2000-11-23 | Dade Behring Inc. | Homogeneous isothermal amplification and detection of nucleic acids using a template switch oligonucleotide |
| US6818395B1 (en) | 1999-06-28 | 2004-11-16 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
| US6232104B1 (en) | 1999-08-17 | 2001-05-15 | Dade Behring Inc. | Detection of differences in nucleic acids by inhibition of spontaneous DNA branch migration |
| DK1218542T3 (da) | 1999-09-13 | 2004-08-02 | Nugen Technologies Inc | Fremgangsmåder og sammensætninger til lineær isotermisk amplifikation af polynukleotidsekvenser |
| US7244559B2 (en) | 1999-09-16 | 2007-07-17 | 454 Life Sciences Corporation | Method of sequencing a nucleic acid |
| US6309836B1 (en) | 1999-10-05 | 2001-10-30 | Marek Kwiatkowski | Compounds for protecting hydroxyls and methods for their use |
| US20030022318A1 (en) | 2000-01-25 | 2003-01-30 | Epiclone, Inc. | Method for thermocycling amplification of nucleic acid sequences and the generation of related peptides thereof |
| WO2001083696A2 (en) | 2000-04-28 | 2001-11-08 | Digital Gene Tech Inc | Methods for rapid isolation and sequence determination of gene-specific sequences |
| JP2001333800A (ja) | 2000-05-30 | 2001-12-04 | Unitech Kk | Ｒｎａ量およびｄｎａ量の比較検出方法 |
| CA2412721A1 (en) | 2000-06-26 | 2002-01-03 | Nugen Technologies, Inc. | Methods and compositions for transcription-based nucleic acid amplification |
| JP2004537257A (ja) | 2000-10-06 | 2004-12-16 | ニューゲン テクノロジーズ， インコーポレイテッド | 核酸配列の検出および／または定量のための、方法およびプローブ |
| AR031640A1 (es) | 2000-12-08 | 2003-09-24 | Applied Research Systems | Amplificacion isotermica de acidos nucleicos en un soporte solido |
| CA2430329A1 (en) | 2000-12-13 | 2002-06-20 | Nugen Technologies, Inc. | Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof |
| US20040058373A1 (en) | 2001-01-31 | 2004-03-25 | Winkler Matthew M. | Competitive amplification of fractionated targets from multiple nucleic acid samples |
| MXPA02012739A (es) | 2001-03-09 | 2004-04-20 | Nugen Technologies Inc | Metodos y composiciones para amplificacion de secuencias de arn. |
| US6632611B2 (en) | 2001-07-20 | 2003-10-14 | Affymetrix, Inc. | Method of target enrichment and amplification |
| US20030104432A1 (en) | 2001-07-27 | 2003-06-05 | The Regents Of The University Of California | Methods of amplifying sense strand RNA |
| JP2005519621A (ja) | 2002-03-11 | 2005-07-07 | ニューゲン テクノロジーズ， インコーポレイテッド | ３’一本鎖部分を含む二本鎖ｄｎａを生成する方法および組換えのためのこれらの複合体の使用 |
| AU2003222178A1 (en) | 2002-03-29 | 2003-10-13 | Nugen Technologies, Inc. | Single primer isothermal nucleic acid amplification-enhanced analyte detection and quantification |
| AU2003279697A1 (en) | 2002-05-17 | 2004-02-16 | Nugen Technologies, Inc. | Methods for fragmentation, labeling and immobilizaton of nucleic acids |
| AU2003240795A1 (en) | 2002-05-24 | 2003-12-12 | Invitrogen Corporation | Nested pcr employing degradable primers |
| US6852494B2 (en) | 2003-01-10 | 2005-02-08 | Linden Technologies, Inc. | Nucleic acid amplification |
| ES2263862T3 (es) | 2003-03-07 | 2006-12-16 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones. |
| US7402386B2 (en) | 2003-04-14 | 2008-07-22 | Nugen Technologies, Inc. | Global amplification using random priming by a composite primer |
| DE602004029694D1 (de) | 2003-08-11 | 2010-12-02 | Univ Georgia State Res Found | Rna-nachweis und quantifizierung |
| US7226720B2 (en) | 2003-09-08 | 2007-06-05 | General Electric Company | Limited play data storage media and method for limiting access to data thereon |
| AU2004286201B2 (en) | 2003-09-10 | 2010-09-09 | Altheadx, Inc. | Expression profiling using microarrays |
| US7169560B2 (en) | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
| US20080021205A1 (en) | 2003-12-11 | 2008-01-24 | Helen Blau | Methods and Compositions for Use in Preparing Hairpin Rnas |
| CN1925855B (zh) | 2003-12-19 | 2010-06-16 | 普莱希科公司 | 开发Ret调节剂的化合物和方法 |
| WO2005065321A2 (en) | 2003-12-29 | 2005-07-21 | Nugen Technologies, Inc. | Methods for analysis of nucleic acid methylation status and methods for fragmentation, labeling and immobilization of nucleic acids |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| US20070070349A1 (en) | 2005-09-23 | 2007-03-29 | Helicos Biosciences Corporation | Optical train and method for TIRF single molecule detection and analysis |
| US7220549B2 (en) | 2004-12-30 | 2007-05-22 | Helicos Biosciences Corporation | Stabilizing a nucleic acid for nucleic acid sequencing |
| EP1896610A2 (en) | 2005-05-03 | 2008-03-12 | Handylab, Inc. | Lyophilized pellets |
| CA2621267A1 (en) | 2005-09-07 | 2007-03-15 | Nugen Technologies, Inc. | Improved nucleic acid amplification procedure |
| WO2007057652A1 (en) | 2005-11-15 | 2007-05-24 | Solexa Limited | Method of target enrichment |
| US7282337B1 (en) | 2006-04-14 | 2007-10-16 | Helicos Biosciences Corporation | Methods for increasing accuracy of nucleic acid sequencing |
| US20090275486A1 (en) | 2006-05-16 | 2009-11-05 | Nurith Kurn | Nucleic acid separation and purification method based on reversible charge interactions |
| US20100022403A1 (en) | 2006-06-30 | 2010-01-28 | Nurith Kurn | Methods for fragmentation and labeling of nucleic acids |
| WO2008093098A2 (en) | 2007-02-02 | 2008-08-07 | Illumina Cambridge Limited | Methods for indexing samples and sequencing multiple nucleotide templates |
| US8685899B2 (en) | 2007-02-14 | 2014-04-01 | Genisphere Inc. | Methods, reagents and kits for detection of nucleic acid molecules |
| US20090093378A1 (en) | 2007-08-29 | 2009-04-09 | Helen Bignell | Method for sequencing a polynucleotide template |
| US20100248310A1 (en) | 2007-10-22 | 2010-09-30 | Monoquant Pty Ltd. | Method of dna amplification |
| AU2009205523A1 (en) | 2008-01-14 | 2009-07-23 | Applied Biosystems, Llc | Compositions, methods, and kits for detecting ribonucleic acid |
| WO2009102878A2 (en) | 2008-02-12 | 2009-08-20 | Nugen Technologies, Inc. | Method for archiving and clonal expansion |
| WO2009117698A2 (en) | 2008-03-21 | 2009-09-24 | Nugen Technologies, Inc. | Methods of rna amplification in the presence of dna |
| US8029993B2 (en) | 2008-04-30 | 2011-10-04 | Population Genetics Technologies Ltd. | Asymmetric adapter library construction |
| CN101270395A (zh) | 2008-05-08 | 2008-09-24 | 重庆大学 | 柑桔衰退病毒一步法实时荧光反转录聚合酶链式反应固相化试剂盒及其检测方法 |
| US20110172105A1 (en) | 2008-06-04 | 2011-07-14 | Salk Institute For Biological Studies | GREPSEQ: An Almost Inexhaustible, Cost-Effective, High-Throughput Protocol for the Generation of Selector Sequences |
| CA2730190A1 (en) | 2008-07-14 | 2010-01-21 | Queen's University At Kingston | Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
| WO2010077288A2 (en) | 2008-12-09 | 2010-07-08 | The Salk Institute For Biological Studies | Methods for identifying differences in alternative splicing between two rna samples |
| JP2010143860A (ja) | 2008-12-19 | 2010-07-01 | Chisso Corp | タンパク質の安定化剤 |
| WO2010083046A2 (en) | 2009-01-15 | 2010-07-22 | The Salk Institute For Biological Studies | Methods for using next generation sequencing to identify 5-methyl cytosines in the genome |
| US20100286143A1 (en) | 2009-04-24 | 2010-11-11 | Dora Dias-Santagata | Methods and materials for genetic analysis of tumors |
| WO2011014811A1 (en) | 2009-07-31 | 2011-02-03 | Ibis Biosciences, Inc. | Capture primers and capture sequence linked solid supports for molecular diagnostic tests |
| EP2464738A4 (en) | 2009-08-12 | 2013-05-01 | Nugen Technologies Inc | METHODS, COMPOSITIONS, AND KITS FOR GENERATING NUCLEIC ACID PRODUCTS SUBSTANTIALLY FREE OF MATRIX NUCLEIC ACID |
| EP2475777A4 (en) | 2009-09-11 | 2013-03-06 | Nugen Technologies Inc | COMPOSITIONS AND METHODS FOR COMPLETE TRANSCRIPTOMAL ANALYSIS |
| WO2011053987A1 (en) | 2009-11-02 | 2011-05-05 | Nugen Technologies, Inc. | Compositions and methods for targeted nucleic acid sequence selection and amplification |
| CA2786473A1 (en) | 2010-01-08 | 2011-07-14 | Qiagen Gaithersburg, Inc. | Materials and methods for isothermal nucleic acid amplification |
| EP2370599B1 (en) * | 2010-01-19 | 2015-01-21 | Verinata Health, Inc | Method for determining copy number variations |
| GB201008125D0 (en) | 2010-05-14 | 2010-06-30 | Biofortuna Ltd | Tissue typing assays and kits |
| EP2580378A4 (en) | 2010-06-08 | 2014-01-01 | Nugen Technologies Inc | MULTIPLEX SEQUENCING METHODS AND COMPOSITION |
| US20120003657A1 (en) | 2010-07-02 | 2012-01-05 | Samuel Myllykangas | Targeted sequencing library preparation by genomic dna circularization |
| EP2606154B1 (en) | 2010-08-20 | 2019-09-25 | Integenx Inc. | Integrated analysis system |
| EP2619329B1 (en) | 2010-09-24 | 2019-05-22 | The Board of Trustees of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target dna using immobilized primers |
| US20120100549A1 (en) | 2010-10-01 | 2012-04-26 | Ibis Biosciences, Inc. | Targeted genome amplification methods |
| CN103608466B (zh) | 2010-12-22 | 2020-09-18 | 纳特拉公司 | 非侵入性产前亲子鉴定方法 |
| WO2012103154A1 (en) | 2011-01-24 | 2012-08-02 | Nugen Technologies, Inc. | Stem-loop composite rna-dna adaptor-primers: compositions and methods for library generation, amplification and other downstream manipulations |
| US8722585B2 (en) * | 2011-05-08 | 2014-05-13 | Yan Wang | Methods of making di-tagged DNA libraries from DNA or RNA using double-tagged oligonucleotides |
| JP6040227B2 (ja) * | 2011-05-19 | 2016-12-07 | アジーナ バイオサイエンス， インコーポレイテッド | マルチプレックス核酸同定のための製品およびプロセス |
| WO2013059746A1 (en) | 2011-10-19 | 2013-04-25 | Nugen Technologies, Inc. | Compositions and methods for directional nucleic acid amplification and sequencing |
| US20130123117A1 (en) | 2011-11-16 | 2013-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Capture probe and assay for analysis of fragmented nucleic acids |
| EP2807292B1 (en) | 2012-01-26 | 2019-05-22 | Tecan Genomics, Inc. | Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation |
| EP2847353B1 (en) | 2012-05-10 | 2022-01-19 | The General Hospital Corporation | Methods for determining a nucleotide sequence |
| CA2877094A1 (en) | 2012-06-18 | 2013-12-27 | Nugen Technologies, Inc. | Compositions and methods for negative selection of non-desired nucleic acid sequences |
| ES2769796T3 (es) * | 2012-07-03 | 2020-06-29 | Integrated Dna Tech Inc | Oligonucleótidos de bloqueo aumentados en Tm y señuelos para un enriquecimiento de diana mejorado y una selección fuera de diana reducida |
| US20150011396A1 (en) | 2012-07-09 | 2015-01-08 | Benjamin G. Schroeder | Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing |
| NZ630698A (en) * | 2012-09-25 | 2017-03-31 | Agriculture Victoria Serv Pty | Method of producing a normalised nucleic acid library using solid state capture material |
| WO2014071295A1 (en) | 2012-11-02 | 2014-05-08 | Enzymatics Inc. | Methods and kits for nucleic acid sample preparation for sequencing |
| EP2959016A4 (en) | 2013-02-21 | 2016-10-12 | Toma Biosciences Inc | METHOD, COMPOSITIONS AND NUCLEIC ACID ANALYSIS KITS |
| WO2014138385A1 (en) | 2013-03-06 | 2014-09-12 | Ohio State Innovation Foundation | Isothermal amplification of nuleic acid, and library preparation and clone generation in sequencing |
| US20140274729A1 (en) | 2013-03-15 | 2014-09-18 | Nugen Technologies, Inc. | Methods, compositions and kits for generation of stranded rna or dna libraries |
| EP3611262B1 (en) | 2013-03-15 | 2020-11-11 | Lineage Biosciences, Inc. | Methods of sequencing the immune repertoire |
| GB2525568B (en) | 2013-03-15 | 2020-10-14 | Abvitro Llc | Single cell barcoding for antibody discovery |
| US9822408B2 (en) | 2013-03-15 | 2017-11-21 | Nugen Technologies, Inc. | Sequential sequencing |
| WO2015073711A1 (en) | 2013-11-13 | 2015-05-21 | Nugen Technologies, Inc. | Compositions and methods for identification of a duplicate sequencing read |
| US9689027B2 (en) | 2013-11-15 | 2017-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | High efficiency multiplexed nucleic acid capture in a structured microenvironment |
| US10767222B2 (en) | 2013-12-11 | 2020-09-08 | Accuragen Holdings Limited | Compositions and methods for detecting rare sequence variants |
| WO2015089496A1 (en) | 2013-12-15 | 2015-06-18 | Academia Sinica | Methods for full-length amplification of double-stranded linear nucleic acids of unknown sequences |
| WO2015112948A2 (en) | 2014-01-27 | 2015-07-30 | Iafrate Anthony John | Methods for determining a nucleotide sequence |
| EP3099819A4 (en) | 2014-01-27 | 2018-01-10 | Archerdx, Inc. | Isothermal methods and related compositions for preparing nucleic acids |
| EP3099820A4 (en) | 2014-01-27 | 2018-01-03 | The General Hospital Corporation | Methods of preparing nucleic acids for sequencing |
| ES2781323T3 (es) | 2014-06-23 | 2020-09-01 | Regeneron Pharma | Montaje de ADN mediado por nucleasas |
| EP3950944A1 (en) | 2014-09-15 | 2022-02-09 | AbVitro LLC | High-throughput nucleotide library sequencing |
| WO2016138500A1 (en) | 2015-02-27 | 2016-09-01 | Cellular Research, Inc. | Methods and compositions for barcoding nucleic acids for sequencing |
| EP3332024B1 (en) | 2015-08-06 | 2020-10-28 | F.Hoffmann-La Roche Ag | Target enrichment by single probe primer extension |
| EP3443149B1 (en) | 2016-04-15 | 2024-08-14 | University Health Network (UHN) | Hybrid-capture sequencing for determining immune cell clonality |
| WO2018053365A1 (en) | 2016-09-15 | 2018-03-22 | ArcherDX, Inc. | Methods of nucleic acid sample preparation for analysis of cell-free dna |
| US10704082B2 (en) | 2016-09-15 | 2020-07-07 | ArcherDX, Inc. | Methods of nucleic acid sample preparation |
| US20220282305A1 (en) | 2016-09-15 | 2022-09-08 | Archerdx, Llc | Methods of nucleic acid sample preparation |
| ES2940620T3 (es) | 2016-11-02 | 2023-05-09 | Archerdx Llc | Métodos de preparación de muestras de ácido nucleico para la secuenciación del repertorio inmunitario |
-
2017
- 2017-09-15 US US15/706,642 patent/US10704082B2/en active Active
- 2017-09-15 AU AU2017328950A patent/AU2017328950B2/en active Active
- 2017-09-15 CN CN201780070128.7A patent/CN109937254B/zh active Active
- 2017-09-15 WO PCT/US2017/051924 patent/WO2018053362A1/en not_active Ceased
- 2017-09-15 EP EP21193343.7A patent/EP3933039A1/en not_active Withdrawn
- 2017-09-15 CA CA3037185A patent/CA3037185A1/en active Pending
- 2017-09-15 EP EP17851671.2A patent/EP3512947B1/en active Active
- 2017-09-15 ES ES17851671T patent/ES2903357T3/es active Active
- 2017-09-15 JP JP2019514776A patent/JP6997772B2/ja active Active
-
2020
- 2020-07-02 US US16/919,238 patent/US11795492B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11795492B2 (en) | Methods of nucleic acid sample preparation | |
| US11390905B2 (en) | Methods of nucleic acid sample preparation for analysis of DNA | |
| JP2019531072A5 (https=) | ||
| JP7483824B2 (ja) | 免疫レパートリーシーケンシングのための核酸サンプル調製の方法 | |
| JP2019532629A5 (https=) | ||
| JP2018522543A (ja) | 分子タグ付けのための方法、システム、組成物、キット、装置、及びコンピュータ可読媒体 | |
| CN110741096B (zh) | 用于检测循环肿瘤dna的组合物和方法 | |
| US20220282305A1 (en) | Methods of nucleic acid sample preparation | |
| HK40066065A (en) | Methods of nucleic acid sample preparation | |
| JP2022546485A (ja) | 腫瘍高精度アッセイのための組成物および方法 |